NCT06117644View on ClinicalTrials.gov

The Efficacy of Double-dose Furmonertinib in the Treatment of Patients With Slow Osimertinib-resistant NSCLC

Not yet recruitingOBSERVATIONAL
Enrollment

30

Participants

Timeline

Start Date

November 1, 2023

Primary Completion Date

November 1, 2025

Study Completion Date

October 1, 2026

Conditions
Non Small Cell Lung CancerEGFR Gene MutationNon Small Cell Lung Cancer Stage IIIANon-small Cell Lung Cancer Stage IV
Interventions
DRUG

Furmonertinib

Furmonertinib 40 mg/tablet, 4 tablets, QD

All Listed Sponsors
lead

Daping Hospital and the Research Institute of Surgery of the Third Military Medical University

OTHER

NCT06117644 - The Efficacy of Double-dose Furmonertinib in the Treatment of Patients With Slow Osimertinib-resistant NSCLC | Biotech Hunter | Biotech Hunter